Trial results

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252 on ClinicalTrials.gov · last registry update 2026-03-23

An unusually large phase 2: 414 participants, more than double the 114 typical for the stage. The sponsor logged completion for 8 January 2026. Primary outcome, as filed: Percent Change From Baseline in Body Weight. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

414

Started

2023-09-21

Primary completion

2026-01-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight

Conditions studied

Type 2 Diabetes · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.